Ori Biotech receives Frost & Sullivan’s 2021 Global Enabling Technology Leadership Award for cell and gene therapy manufacturing

Ori Biotech receives Frost & Sullivan’s 2021 Global Enabling Technology Leadership Award for cell and gene therapy manufacturing  

London, UK, March 31, 2021 – Ori Biotech Ltd., an innovator in cell and gene therapy (CGT) manufacturing technologies, today announces that Frost & Sullivan has awarded Ori Biotech the 2021 Global Enabling Technology Leadership Award in the cell and gene therapy manufacturing market.  

Frost & Sullivan presented the award to Ori Biotech following a comprehensive assessment of the global shortlist by its panel of growth pipeline analysts. Criteria for the award involved analysis of technology, best practices, products, and services of the shortlisted competitive companies and how they would provide solutions to current and future challenges in the marketplaces in which they operate. 

Key to its decision, Frost & Sullivan recognized Ori Biotech’s ability to overcome a fundamental challenge within cell and gene therapy. This challenge is the current manufacturing processes that are highly manual, time consuming, and costly, directly affecting the ability to enable widespread access to potentially life-saving treatments to patients. In its evaluation process, Frost & Sullivan highlighted Ori’s commitment to innovation and creativity, its early commercialization successes, market, price, and performance value. 

“Ori Biotech has developed a one-of-its-kind automated platform which increases throughput, improves quality, and decreases manufacturing costs, aligning with Ori’s mission to enable patient access,” said Supriya Lala, Best Practices Research Analyst at Frost & Sullivan. 

“The cell and gene therapy sector has made great steps in gaining regulatory approval and beginning commercialization of this new generation of life-saving cell and gene therapies. Achieving widespread access for patients will be impossible, however, if these potentially curative therapies cannot be manufactured affordably in large volumes,” said Jason C. Foster, CEO, Ori Biotech. “Frost & Sullivan has recognized that these challenges threaten the viability of the entire cell and gene therapy industry. We are honored that they have identified Ori’s efforts to deliver practical, workable manufacturing solutions that will directly answer some of the biggest questions in the cell and gene therapy sector – particularly manufacturing throughput, quality, cost, and barrier to patient access.”

About Ori Biotech

Ori is a London and New Jersey based cell and gene therapy (CGT) manufacturing technology company. Ori has developed a proprietary, flexible manufacturing platform that closes, automates and standardizes CGT manufacturing allowing therapeutics developers to further develop and bring their products to market at commercial scale. The promise of the full stack Ori platform is to fully automate CGT manufacturing to increase throughput, improve quality and decrease costs by combining hardware, software and data services. 

Ori was founded by Professor Chris Mason (AVRO) and Dr. Farlan Veraitch (UCL) and has brought together a seasoned Board and executive management team with over 100 years of pharmaceutical, CGT and venture building experience including CEO Jason C. Foster (Indivior), CBO Jason Jones (Miltenyi Biotec), VP Tom Heathman (Minaris), VP David Smith (Minaris) alongside expert advisers like Bruce Levine, Anthony Davies and Annalisa Jenkins. For more information, visit http://www.oribiotech.com.